Incidence and risk factors of atherosclerotic renal artery stenosis in elderly patients with refractory hypertension
-
摘要:
目的 调查老年难治性高血压患者动脉粥样硬化性肾动脉狭窄(ARAS)的发病状况，并分析其危险因素，为临床早期诊治ARAS提供依据。 方法 回顾性分析2016年2月—2021年2月在西安交通大学第一附属医院心内科门诊就诊的老年难治性高血压患者216例的临床资料，根据肾动脉彩超和造影结果分为ARAS组(48例)和非ARAS组(168例)。比较2组临床资料，并分析患者发生ARAS的危险因素。 结果 216例患者肾动脉超声提示ARAS共62例(28.70%)，经肾动脉造影结果确诊ARAS共48例(22.22%)。ARAS组合并糖尿病、高脂血症、外周血管疾病、冠心病、肾功能不全比例分别为47.92%(23/48)、68.75%(33/48)、39.58%(19/48)、54.17%(26/48)、52.08%(25/48)，明显高于非ARAS组[30.36%(51/168)、51.19%(86/168)、18.45%(31/168)、34.52%(58/168)、26.79%(45/168)，均P＜0.05]；多因素logistic回归分析显示，合并外周血管疾病(OR=2.651, 95% CI：1.039~6.764)、肾功能不全(OR=2.713, 95% CI：1.106~6.656)是老年难治性高血压患者发生ARAS的独立危险因素。 结论 老年难治性高血压患者ARAS的发生率较高，合并外周血管疾病、肾功能不全是患者发生ARAS的独立危险因素。 Abstract:Objective To investigate the incidence of atherosclerotic renal artery stenosis (ARAS) in elderly patients with refractory hypertension and to analyse its risk factors, to provide evidence for the early clinical diagnosis and treatment of ARAS. Methods The clinical data of 216 elderly patients with refractory hypertension treated in the Cardiology Department of the First Affiliated Hospital of Xi ' an Jiaotong University from February 2016 to February 2021 were retrospectively analysed. According to the results of renal artery color Doppler ultrasonography and angiography, they were divided into ARAS (n=48) and non-ARAS (n=168) groups. The clinical data of the two groups were compared, and the risk factors for ARAS were analysed. Results In 216 patients, 62 cases (28.70%) were diagnosed as ARAS by renal arterial ultrasonography, and 48 cases (22.22%) were confirmed as ARAS by renal arteriography. The proportions of diabetes mellitus, hyperlipidemia, peripheral vascular disease, coronary heart disease, renal insufficiency in the ARAS group were 47.92% (23/48), 68.75% (33/48), 39.58% (19/48), 54.17% (26/48) and 52.08% (25/48), respectively, significantly higher than those in the non-ASAR group [30.36% (51/168), 51.19% (86/168), 18.45% (31/168), 34.52% (58/168) and 26.79% (45/168), respectively, all P < 0.05]. Multivariate logistic-regression analysis showed that peripheral vascular disease (OR=2.651, 95% CI: 1.039-6.764) and renal insufficiency (OR=2.713, 95% CI: 1.106-6.656) were independent risk factors for ARAS in elderly patients with refractory hypertension. Conclusion Elderly patients with refractory hypertension have a higher incidence of ARAS, and peripheral vascular disease and renal insufficiency are independent risk factors affecting ARAS occurrence. -
Key words:
- Refractory senile hypertension /
- Atherosclerosis /
- Renal artery stenosis /
- Risk factors
-
表 1 2组老年难治性高血压患者相关临床资料比较
Table 1. Comparison of relevant clinical data in two groups of elderly patients with refractory hypertension
组别 例数 性别[例(%)] 年龄(x±s, 岁) 高血压病程(x±s, 年) 吸烟[例(%)] 糖尿病[例(%)] 男性 女性 有 无 有 无 ARAS组 48 26(54.17) 22(45.83) 68.69±1.58 15.63±2.53 11(22.92) 37(77.08) 23(47.92) 25(52.08) 非ARAS组 168 89(52.98) 79(47.02) 68.79±1.68 15.81±2.79 36(21.43) 132(78.57) 51(30.36) 117(69.64) 统计量 0.021a 0.368b 0.402b 0.049a 5.111a P值 0.884 0.713 0.688 0.826 0.024 组别 例数 高脂血症[例(%)] 外周血管疾病[例(%)] 冠心病[例(%)] 肾功能不全[例(%)] 高尿酸血症[例(%)] 有 无 有 无 有 无 有 无 有 无 ARAS组 48 33(68.75) 15(31.25) 19(39.58) 29(60.42) 26(54.17) 22(45.83) 25(52.08) 23(47.92) 8(16.67) 40(83.33) 非ARAS组 168 86(51.19) 82(48.81) 31(18.45) 137(81.55) 58(34.52) 110(65.48) 45(26.79) 123(73.21) 33(19.64) 135(80.36) 统计量 4.653a 9.371a 6.061a 10.907a 0.215a P值 0.031 0.002 0.014 0.001 0.643 注：a为χ2值，b为t值。 
下载: 导出CSV
表 2 各变量赋值方法
Table 2. Methods of variable assignment
变量 赋值方法 糖尿病 无=0，有=1 高脂血症 无=0，有=1 外周血管疾病 无=0，有=1 冠心病 无=0，有=1 肾功能不全 无=0，有=1 ARAS 无=0，有=1
下载: 导出CSV
表 3 老年难治性高血压患者ARAS影响因素的多因素logistic回归分析
Table 3. Multivariate logistic regression analysis of influencing factors of ARAS in elderly patients with refractory hypertension
变量 B SE Wald χ2 P值 OR值 95% CI 糖尿病 0.423 0.236 1.958 0.162 1.526 0.961~2.424 高脂血症 0.399 0.218 1.868 0.172 1.490 0.972~2.285 外周血管疾病 0.975 0.478 11.958 0.001 2.651 1.039~6.764 冠心病 0.449 0.241 2.195 0.138 1.567 0.977~2.512 肾功能不全 0.998 0.458 15.468 < 0.001 2.713 1.106~6.656
下载: 导出CSV
-
[1] 卢旭, 余蕾蕾, 陈光辉. 小剂量螺内酯在老年难治性高血压患者中的疗效及安全性分析[J]. 河北医学, 2017, 23(8): 1294-1301. https://www.cnki.com.cn/Article/CJFDTOTAL-HCYX201708018.htmLU X, YU L L, CHEN G H. Efficacy and safety of low-dose spironolactone in elderly patients with refractory hypertension[J]. Hebei Medicine, 2017, 23(8): 1294-1301. https://www.cnki.com.cn/Article/CJFDTOTAL-HCYX201708018.htm [2] 任若鸾, 沈珈谊, 韦铁民, 等. 动脉粥样硬化性肾动脉狭窄与心血管疾病研究进展[J]. 心血管病学进展, 2019, 40(1): 135-138. https://www.cnki.com.cn/Article/CJFDTOTAL-XXGB201901037.htmREN R Y, SHEN J Y, WEI T M, et al. Research progress of atherosclerotic renal artery stenosis and cardiovascular disease[J]. Advances in Cardiovascular Diseases, 2019, 40(1): 135-138. https://www.cnki.com.cn/Article/CJFDTOTAL-XXGB201901037.htm [3] 陈强, 左丙杰, 刘岩, 等. 老年患者动脉粥样硬化性肾动脉狭窄的危险因素分析[J]. 中华老年病研究电子杂志, 2020, 7(2): 36-39. https://www.cnki.com.cn/Article/CJFDTOTAL-LNBY202002015.htmCHEN Q, ZUO B J, LIU Y, et al. Analysis of risk factors for arteriosclerosis renal artery stenosis[J]. Chinese Journal of Geriatrics Research(Electronic Editon), 2020, 7(2): 36-39. https://www.cnki.com.cn/Article/CJFDTOTAL-LNBY202002015.htm [4] 郭慧, 叶志斌. 动脉粥样硬化性肾动脉狭窄的治疗学进展[J]. 复旦学报(医学版), 2018, 45(3): 418-422. https://www.cnki.com.cn/Article/CJFDTOTAL-SHYK201803022.htmGUO H, YE Z B. The theraputic progress of atherosclerotic renal artery stenosis[J]. Fudan University Journal of Medical Sciences, 2018, 45(3): 418-422. https://www.cnki.com.cn/Article/CJFDTOTAL-SHYK201803022.htm [5] 蒋雄京, 董徽. 2018美国心脏协会难治性高血压的诊治管理科学声明[J]. 中华高血压杂志, 2018, 26(12): 1101-1104. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ201812001.htmJIANG X J, DONG H. 2018 American Heart Association Scientific Statement on the Management of Treatment-Resistant Hypertension[J]. Chinese Journal of Hypertension, 2018, 26(12): 1101-1104. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ201812001.htm [6] 江瑛, 张丽, 王海军, 等. 中老年动脉粥样硬化性肾动脉狭窄预测因子分析[J]. 中华保健医学杂志, 2018, 20(5): 371-373. https://www.cnki.com.cn/Article/CJFDTOTAL-JFJB201805004.htmJIANG Y, ZHANG L, WANG H J, et al. Study on clinical predictor of atherosclerotic renal artery stenosis in middile-aged and elderly patients[J]. Chinese Journal of Health Care and Medicine, 2018, 20(5): 371-373. https://www.cnki.com.cn/Article/CJFDTOTAL-JFJB201805004.htm [7] SAXENA T, ALI A O, SAXENA M. Pathophysiology of essential hypertension: An update[J]. Expert Rev Cardiovasc Ther, 2018, 16(12): 879-887. [8] 艾虎, 张慧平, 唐国栋, 等. 老年难治性高血压患者肾动脉粥样硬化性狭窄的发病情况及相关危险因素分析[J]. 中华老年医学杂志, 2018, 37(3): 264-267. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202209019.htmAI H, ZHANG H P, TANG G D, et al. Prevalence and risk factors for atherosclerotic renal artery stenosis in elderly patients with refractory hypertension[J]. Chinese Journal of Geriatrics, 2018, 37(3): 264-267. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202209019.htm [9] 陈阿千, 李凌. 冠心病合并高血压患者动脉粥样硬化性肾动脉狭窄的危险因素分析[J]. 河南医学研究, 2021, 30(15): 2711-2714. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYX202115007.htmCHEN A G, LI L. Risk factors of atherosclerotic renal artery stenosis in patients with coronary heart disease and hypertension[J]. Henan Medical Research, 2021, 30(15): 2711-2714. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYX202115007.htm [10] 李秀锋, 杨乃宁, 梁国威, 等. 肾动脉粥样硬化性肾动脉狭窄早期实验室筛查[J]. 标记免疫分析与临床, 2020, 27(10): 1715-1718. https://www.cnki.com.cn/Article/CJFDTOTAL-BJMY202010017.htmLI X F, YANG N N, LIANG G W, et al. The early laboratory screening of atherosclerotic renal artery stenosis[J]. Labeled Immunoassays and Clinical Medicine, 2020, 27(10): 1715-1718. https://www.cnki.com.cn/Article/CJFDTOTAL-BJMY202010017.htm [11] 骆雷鸣. 外周动脉疾病的研究进展与前景[J]. 中华老年心脑血管病杂志, 2018, 20(5): 449-453. https://www.cnki.com.cn/Article/CJFDTOTAL-LNXG201805001.htmLUO L M. Advances and prospects in research on peripheral artery disease[J]. Chinese Journal of Geriatric Heart Brain and Vessel Diseases, 2018, 20(5): 449-453. https://www.cnki.com.cn/Article/CJFDTOTAL-LNXG201805001.htm [12] 王丽. 胱抑素C与肌酐、尿素氮联合检测在肾功能损害中的应用[J]. 中国医药指南, 2021, 19(4): 108-109. https://www.cnki.com.cn/Article/CJFDTOTAL-YYXK202104050.htmWANG L. Application of cystatin C combined with creatinine and urea nitrogen in renal impairment[J]. Guide of China Medicine, 2021, 19(4): 108-109. https://www.cnki.com.cn/Article/CJFDTOTAL-YYXK202104050.htm [13] 刘仕俊, 刘庆敏, 丁华, 等. 影响杭州市社区老年高血压控制的因素[J]. 中华高血压杂志, 2021, 29(3): 251-256.LIU S J, LIU Q M, DING H, et al. The factors correlated with the blood pressure control among the elderly hypertension in Hangzhou[J]. Chinese Journal of Hypertension, 2021, 29(3): 251-256. [14] 王宙, 沈静, 刘洋, 等. 中西药联合降脂对肾动脉粥样硬化性高血压大鼠炎症反应的影响[J]. 中国循证心血管医学杂志, 2019, 11(4): 428-430, 434. https://www.cnki.com.cn/Article/CJFDTOTAL-PZXX201904012.htmWANG Z, SHEN J, LIU Y, et al. Influence of lipid-lowering therapy integrating traditional Chinese and Western medicinals on inflammatory response in rats with renal atherosclerotic hypertension[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine, 2019, 11(4): 428-430, 434. https://www.cnki.com.cn/Article/CJFDTOTAL-PZXX201904012.htm [15] 李晖, 孙晓凤, 张源明. 动脉粥样硬化性肾动脉狭窄的发生率及其相关危险因素分析[J]. 中国动脉硬化杂志, 2011, 19(5): 427-430. https://www.cnki.com.cn/Article/CJFDTOTAL-KDYZ201105013.htmLI H, SUN X F, ZHANG Y M. Incidence and risk factors of atherosclerotic renal artery stenosis[J]. Chinese Journal of Arteriosclerosis, 2011, 19(5): 427-430. https://www.cnki.com.cn/Article/CJFDTOTAL-KDYZ201105013.htm [16] 宋建龙, 王梓, 魏建林, 等. 中青年急性缺血性脑血管病大脑中动脉斑块特点分析[J]. 中华全科医学, 2021, 19(11): 1811-1814. doi: 10.16766/j.cnki.issn.1674-4152.002173SONG J L, WANG Z, WEI J L, et al. Analysis on the characteristics of middle cerebral arterial plaque in young and middle-aged patients with acute ischemic cerebrovascular disease[J]. Chinese Journal of General Practice, 2021, 19(11): 1811-1814. doi: 10.16766/j.cnki.issn.1674-4152.002173 -
点击查看大图
表(3)
计量
- 文章访问数: 178
- HTML全文浏览量: 68
- PDF下载量: 2
- 被引次数: 0
